- Market Radar
- /
- RGC
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About RGC
6/30/2025
Comprehensive Analysis
Financial Health
- Balance Sheet Strength: Regencell Bioscience (RGC) has transformed from a distressed position in 2020 (negative equity, $2.65M liabilities) to a well-capitalized entity by 2023, with total equity of $12.03M and total assets of $12.62M. Liquidity ratios (current ratio ~28x, quick ratio ~28x) are exceptionally strong, indicating robust short-term solvency.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing